NCT02024932View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 4, 2014

Primary Completion Date

April 13, 2016

Study Completion Date

April 13, 2016

Conditions
Spinal and Bulbar Muscular Atrophy
Interventions
DRUG

BVS857

BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

DRUG

Placebo

Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..

Trial Locations (6)

2100

Novartis Investigative Site, Copenhagen

20892

National Institutes of Health, Bethesda

35128

Novartis Investigative Site, Padua

43210

Novartis Investigative Site, Columbus

89081

Novartis Investigative Site, Ulm

92868

Novartis Investigative Site, Orange

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY